Clinical trials: Escitalopram
Major Depressive Disorder
Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder
The purpose of this clinical research study is to learn whether BMS-562086 is both safe and effective in treating outpatients with major depressive disorder.
- Trial name
- NCT00135421
- Testing
- Pexacerfont, Escitalopram
- Where
- 45 sites in United States
- Volunteers
- 271 people
- Sponsor
- Bristol-Myers Squibb
Major Depressive Disorder
Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
To evaluate the long-term efficacy and safety of brexpiprazole as an adjunctive treatment to an antidepressant treatment (ADT) for adult patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01838681
- Testing
- Brexpiprazole, ADT
- Where
- 107 sites in United States, Bulgaria and 14 more
- Volunteers
- 1,986 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01436162
- Testing
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate )
- Where
- 101 sites in United States, Belgium and 9 more
- Volunteers
- 1,105 people
- Sponsor
- Shire
Major Depressive Disorder
An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder
The main purpose of this study is to evaluate the efficacy of saredutant 100mg once daily in combination with escitalopram 10mg once daily compared to saredutant placebo in combination with escitalopram 10mg once daily in…
- Trial name
- NCT00531622
- Testing
- saredutant (SR48968), escitalopram
- Where
- 6 sites in United States, Argentina and 4 more
- Volunteers
- 643 people
- Sponsor
- Sanofi
Major Depressive Disorder
Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder
To evaluate the efficacy of quetiapine fumarate sustained release (Seroquel SR™) in combination with an antidepressant versus an antidepressant alone in patients with Major Depressive Disorder.
- Trial name
- ONYX (NCT00351910)
- Testing
- Quetiapine, Amitriptyline, Bupropion
- Where
- 72 sites in Australia, Belgium and 10 more
- Volunteers
- 494 people
- Sponsor
- AstraZeneca
Major Depression
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
The study evaluates the ABCB1-genotype dependent efficacy of a quick dose-escalation strategy within 28 days of treatment with approved antidepressants that are known substrates of the P-glycoprotein, an efflux pump of the…
- Trial name
- NCT02237937
- Testing
- Paroxetine, Sertraline, Citalopram
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- HolsboerMaschmeyer NeuroChemie GmbH
Treatment Resistant Depression
Multiple Ascending Dose Phase 1 Study of ALA-3000
This is a randomized, double-blind, placebo-controlled, multiple-dose study of ALA-3000 designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy in subjects with treatment-resistant depression…
- Trial name
- NCT06965569
- Testing
- ALA-3000, escitalopram, sertraline, duloxetine or venlafaxine XR
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Alar Pharmaceuticals Inc.
Depressive Disorder, Depression
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
To assess the long-term safety and tolerability of oral OPC-34712 (brexpiprazole), given in addition to an FDA approved antidepressant (ADT) for the treatment of adults with Major Depressive Disorder (MDD)
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- Orion (NCT01360866)
- Testing
- OPC-34712, Escitalopram, Fluoxetine
- Where
- 142 sites in United States, Canada and 9 more
- Volunteers
- 2,944 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder
The objective of this study is to evaluate the long-term safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01838876
- Testing
- Cariprazine, Antidepressant Therapy (ADT)
- Where
- 90 sites in United States, Puerto Rico
- Volunteers
- 442 people
- Sponsor
- Forest Laboratories
Depression
Using Computer Tasks to Predict Response to Antidepressants
In England over 800,000 patients each year are either newly diagnosed with depression or present with a new episode of depression in primary care.
- Trial name
- NCT02800577
- Testing
- General Practitioner Emotional Test Battery (GP-ETB)
- Where
- 10 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- P1vital Products Limited
Healthy Men
Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male Subjects
To explore a neurophysiological marker (electroencephalography) of cognitive effect of vortioxetine
- Trial name
- NCT02072278
- Testing
- Vortioxetine 10 mg, Vortioxetine 20 mg, Escitalopram 15 mg
- Where
- France
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Anxiety Disorder
Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder
To evaluate the efficacy of a fixed dose of SR58611A (350mg q12) compared to placebo in patients with GeneralizedAnxiety Disorder (GAD) using escitalopram (10 mg qd) as positive control.
- Trial name
- LIBRA (NCT00252343)
- Testing
- SR58611A
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Sanofi